Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

0.3151
-0.0515-14.05%
Post-market: 0.3059-0.0092-2.92%19:59 EDT
Volume:24.26M
Turnover:7.75M
Market Cap:16.07M
PE:-0.13
High:0.3433
Open:0.3200
Low:0.2974
Close:0.3666
Loading ...

Plus Therapeutics Inc. Faces Nasdaq Deficiency Notice Over Delayed Quarterly Report Filing

Reuters
·
24 May

Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
23 May

Plus Therapeutics Inc. Receives Nasdaq Notice for Falling Below $1 Minimum Bid Requirement; Granted 180 Days to Regain Compliance

Reuters
·
20 May

Plus Therapeutics’ Reyobiq™ Shows Clinical Benefit and Safety in the Respect-Lm Clinical Trial for Patients With Leptomeningeal Metastases (Lm)

THOMSON REUTERS
·
14 May

Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
10 May

Plus Therapeutics Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
05 May

Plus Therapeutics Inc. Conducted Special Stockholders Meeting

Reuters
·
03 May

BRIEF-Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors

Reuters
·
23 Apr

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board of Directors

THOMSON REUTERS
·
23 Apr

Press Release: Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Dow Jones
·
23 Apr

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

GlobeNewswire
·
15 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Apr

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Zacks
·
02 Apr

Q4 2024 Plus Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
29 Mar

Plus Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Mar

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
28 Mar

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
28 Mar

Plus Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Plus Therapeutics FY24 EPS $(1.95) Vs. $(4.24) YoY, Grant Revenue $5.8M Up From $4.9M YoY

Benzinga
·
28 Mar

BRIEF-Plus Therapeutics FY Net Income USD -12.978 Million

Reuters
·
28 Mar